Sirolimus therapy after early cyclosporine withdrawal reduced the risk for cancer in adult renal transplantation

Simple item page
dc.contributor.authorCampistol, J.
dc.contributor.authorEris, J.
dc.contributor.authorOberbauer, R.
dc.contributor.authorFriend, P.
dc.contributor.authorHutchison, B.
dc.contributor.authorMorales, J.
dc.contributor.authorClaesson, K.
dc.contributor.authorStallone, G.
dc.contributor.authorRuss, G.
dc.contributor.authorRostaing, L.
dc.contributor.authorKreis, H.
dc.contributor.authorBurke, J.
dc.contributor.authorBrault, Y.
dc.contributor.authorScarola, J.
dc.contributor.authorNeylan, J.
dc.date.issued2006
dc.description© 2006 American Society of Nephrology
dc.description.abstractSirolimus (SRL) is a mammalian target of rapamycin inhibitor that, in contrast to cyclosporine (CsA), has been shown to inhibit rather than promote cancers in experimental models. At 3 mo +/- 2 wk after renal transplantation, 430 of 525 enrolled patients were randomly assigned to remain on SRL-CsA-steroids (ST) or to have CsA withdrawn and SRL troughs increased two-fold (SRL-ST). Median times to first skin and nonskin malignancies were compared between treatments using a survival analysis. Mean annualized rates of skin malignancy were calculated, and the relative risk was determined using a Poisson model. Malignancy-free survival rates for nonskin malignancies were compared using Kaplan-Meier estimates and the log-rank test. At 5 yr, the median time to a first skin carcinoma was delayed (491 versus 1126 d; log-rank test, P = 0.007), and the risk for an event was significantly lower with SRL-ST therapy (relative risk SRL-ST to SRL-CsA-ST 0.346; 95% confidence interval 0.227 to 0.526; P < 0.001, intention-to-treat analysis). The relative risks for both basal and squamous cell carcinomas were significantly reduced. Kaplan-Meier estimates of nonskin cancer were 9.6 versus 4.0% (SRL-CsA-ST versus SRL-ST; P = 0.032, intention-to-treat analysis). Nonskin cancers included those of the lung, larynx, oropharynx, kidney, gastrointestinal tract, prostate, breast, thyroid, and cervix as well as glioma, liposarcoma, astrocytoma, leukemia, lymphoma, and Kaposi's sarcoma. Patients who received SRL-based, calcineurin inhibitor-free therapy after CsA withdrawal at month 3 had a reduced incidence of both skin and nonskin malignancies at 5 yr after renal transplantation compared with those who received SRL therapy combined with CsA. Longer follow-up and additional trials are needed to confirm these promising results.
dc.description.statementofresponsibilityJosep M. Campistol, Josette Eris, Rainer Oberbauer, Peter Friend, Brian Hutchison, José M. Morales, Kerstin Claesson, Giovanni Stallone, Graeme Russ, Lionel Rostaing, Henri Kreis, James T. Burke, Yves Brault, Joseph A. Scarola, John F. Neylan for the Rapamune Maintenance Regimen Study Group
dc.identifier.citationJournal of the American Society of Nephrology, 2006; 17(2):581-589
dc.identifier.doi10.1681/ASN.2005090993
dc.identifier.issn1046-6673
dc.identifier.issn1533-3450
dc.identifier.urihttp://hdl.handle.net/2440/35706
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.source.urihttps://doi.org/10.1681/asn.2005090993
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectSirolimus
dc.subjectCyclosporine
dc.subjectImmunosuppressive Agents
dc.subjectDisease-Free Survival
dc.subjectDrug Therapy, Combination
dc.subjectKidney Transplantation
dc.subjectDrug Administration Schedule
dc.subjectIncidence
dc.subjectRisk Assessment
dc.subjectFollow-Up Studies
dc.subjectDose-Response Relationship, Drug
dc.subjectAdult
dc.titleSirolimus therapy after early cyclosporine withdrawal reduced the risk for cancer in adult renal transplantation
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications